Analyst Reco. GoodRx Holdings, Inc.

Equities

GDRX

US38246G1085

Real-time Estimate Cboe BZX Other stock markets 01:54:39 2024-05-23 pm EDT			5-day change	1st Jan Change
7.285 ^USD	+1.18%		-9.43%	+8.96%

02:45pm	RBC Upgrades GoodRx Holdings to Outperform From Sector Perform, Boosts Price Target to $10 From $8	MT
May. 20	Barclays Adjusts Price Target on GoodRx to $10 From $9, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Upgrades GoodRx Holdings to Outperform From Sector Perform, Boosts Price Target to $10 From $8	08:45am	MT
Barclays Adjusts Price Target on GoodRx to $10 From $9, Maintains Overweight Rating	May. 20	MT
UBS Adjusts Price Target on GoodRx Holdings to $9 From $8, Maintains Neutral Rating	May. 17	MT
Deutsche Bank Adjusts GoodRx Price Target to $9 From $8, Maintains Hold Rating	May. 17	MT
GoodRx Shares Rise After Raymond James Upgrade	May. 16	MT
Raymond James Upgrades GoodRx Holdings to Outperform From Market Perform	May. 16	MT
Deutsche Bank Adjusts GoodRx Price Target to $8 From $9, Maintains Hold Rating	May. 13	MT
KeyBanc Upgrades GoodRx to Overweight From Sector Weight on Increased Conviction Around Monthly Active Customers, Sets $9 Price Target	Apr. 10	MT
GoodRx Shares Jump Following Wells Fargo Upgrade, Price Target Boost	Mar. 25	MT
Wells Fargo Upgrades GoodRx Holdings to Overweight From Equalweight, Adjusts Price Target to $10 From $7.50	Mar. 25	MT
Deutsche Bank Adjusts GoodRx Price Target to $9 From $7, Maintains Hold Rating	Mar. 04	MT
Goldman Sachs Raises GoodRx Holdings' Price Target to $7.50 From $6.50, Maintains Neutral Rating	Mar. 01	MT
UBS Adjusts GoodRx Holdings Price Target to $8 From $5, Maintains Neutral Rating	Mar. 01	MT
TD Cowen Adjusts Price Target on GoodRx Holdings to $14 From $12, Maintains Outperform Rating	Mar. 01	MT
Truist Adjusts Price Target on GoodRx Holdings to $8 From $7.50, Maintains Hold Rating	Mar. 01	MT
JPMorgan Adjusts GoodRx Holdings' Price Target to $7 From $6, Maintains Neutral Rating	Mar. 01	MT
RBC Raises Price Target on GoodRx Holdings to $8 From $7, Keeps Sector Perform Rating	Mar. 01	MT
Leerink Partners Initiates GoodRx Holdings at Outperform Rating With $8 Price Target	Feb. 26	MT
Goldman Sachs Raises Price Target on GoodRx to $6.50 From $6, Maintains Neutral Rating	Jan. 19	MT
RBC Raises Price Target on GoodRx Holdings to $7 From $5, Notes 'Positive Momentum,' Keeps Sector Perform Rating	Jan. 16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. GoodRx Holdings, Inc.

Equities

GDRX

US38246G1085

Analyst Reco.

Filters